Cellyan Biotechnology Co., Ltd
Cellyan Biotechnology operates through two Hong Kong subsidiaries, Joint Cross Border and V-Alliance, and is based in Hong Kong. Its business has two divisions: OTC pharmaceutical cross-border e-commerce supply chain services, and OTC pharmaceutical cross-border procurement and distribution. The supply chain division serves e-commerce platform logistics partners and merchants selling on Chinese online platforms, helping source, register, import, store, package and deliver overseas OTC products to consumers in Mainland China. Its services also include permits, customs documentation and clearance, product information review and warehouse processing. The procurement and distribution division buys overseas OTC medicines and sells them to merchants on Chinese e-commerce platforms and pharmaceutical distributors. Cellyan makes money from fees for supply chain services, including order processing, warehousing, customs clearance and value-added work, and from sales of procured products. Its managed products are sourced from Hong Kong, Taiwan, Japan and certain European countries, and include OTC medicines and some health supplements.
No enriched coverage for $HKPD in the last 7 days.
No SEC Form 4 filings for $HKPD in the last 30 days.
See all $HKPD insider activity →Cellyan Biotechnology (HKPD) announced a 1-for-20 reverse stock split, effective Oct. 26, raising the par value of its shares to $0.02. The split aims to meet Nasdaq's minimum bid price requirement. Fractional shares will be rounded up.
GoPro (GPRO) to merge with Starman Optical for $285M, expanding into AI data centers. Fly-E (FLYE) reports $19.1M revenue, growing in electric mobility. Cellyan (HKPD) operates in cross-border pharmaceutical e-commerce. VivoSim (VIVS) has $10.1M cash, aided by a $5M milestone from Eli Lilly (LLY).
Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) has received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement. The company's share price was below $1.00 for 30 consecutive business days. Cellyan Biotechnology Co., Ltd has 180 calendar days to regain compliance, with a potential additional 180-day grace period, and is currently exploring options to address the deficiency.
Recent HKPD coverage spans financial news, corporate actions and mergers & acquisitions.
The split may cause short-term price volatility and reduced liquidity as shares consolidate.
Business model targets growing Chinese cross‑border pharma demand.
Cellyan Biotechnology's failure to meet Nasdaq's minimum bid price may lead to further decline or delisting, increasing risk for investors.
The announcement of a name change and shareholder approvals indicates strategic repositioning but has caused only a modest decline in stock price, suggesting limited short-term trading impact.
AlphAI scores every news story that mentions HKPD with an AI model for sentiment and relevance, and aggregates insider trades from Cellyan Biotechnology Co., Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
Cellyan Biotechnology (HKPD) announced a 1-for-20 reverse stock split, effective Oct. 26, raising the par value of its shares to $0.02. The split aims to meet Nasdaq's minimum bid price requirement. Fractional shares will be rounded up.
1 min readGoPro (GPRO) to merge with Starman Optical for $285M, expanding into AI data centers. Fly-E (FLYE) reports $19.1M revenue, growing in electric mobility. Cellyan (HKPD) operates in cross-border pharmaceutical e-commerce. VivoSim (VIVS) has $10.1M cash, aided by a $5M milestone from Eli Lilly (LLY).
2 min readCellyan Biotechnology Co., Ltd (Nasdaq: HKPD) has received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement. The company's share price was below $1.00 for 30 consecutive business days. Cellyan Biotechnology Co., Ltd has 180 calendar days to regain compliance, with a potential additional 180-day grace period, and is currently exploring options to address the deficiency.
2 min readHong Kong Pharma Digital (NASDAQ: HKPD) announced that shareholders approved all proposals at its December 12, 2025 annual meeting, including a 10x increase in authorized share capital, a share re-designation, a reverse share split, a share repurchase, and the adoption of an Equity Incentive Plan. Critically, the company's name will change to Cellyan Biotechnology Co., Ltd. Following this news, HKPD stock declined by 4.37%, reflecting a moderate negative market reaction.
2 min read
